859 related articles for article (PubMed ID: 23703580)
1. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
[TBL] [Abstract][Full Text] [Related]
2. The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects.
Hanf R; Millatt LJ; Cariou B; Noel B; Rigou G; Delataille P; Daix V; Hum DW; Staels B
Diab Vasc Dis Res; 2014 Nov; 11(6):440-7. PubMed ID: 25212694
[TBL] [Abstract][Full Text] [Related]
3. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
Cariou B; Staels B
Expert Opin Investig Drugs; 2014 Oct; 23(10):1441-8. PubMed ID: 25164277
[TBL] [Abstract][Full Text] [Related]
4. Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.
Cariou B; Hanf R; Lambert-Porcheron S; Zaïr Y; Sauvinet V; Noël B; Flet L; Vidal H; Staels B; Laville M
Diabetes Care; 2013 Oct; 36(10):2923-30. PubMed ID: 23715754
[TBL] [Abstract][Full Text] [Related]
5. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
6. Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis.
Zhou Z; Deng L; Hu L; Ren Q; Cai Z; Wang B; Li Z; Zhang L
Eur J Pharmacol; 2020 Sep; 882():173300. PubMed ID: 32592770
[TBL] [Abstract][Full Text] [Related]
7. Nuclear control of inflammation and fibrosis in nonalcoholic steatohepatitis: therapeutic potential of dual peroxisome proliferator-activated receptor alpha/delta agonism.
Quintero P; Arrese M
Hepatology; 2013 Dec; 58(6):1881-4. PubMed ID: 23787705
[No Abstract] [Full Text] [Related]
8. The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model.
Liu L; Liu C; Zhao M; Zhang Q; Lu Y; Liu P; Yang H; Yang J; Chen X; Yao Y
PLoS One; 2020; 15(12):e0243911. PubMed ID: 33326461
[TBL] [Abstract][Full Text] [Related]
9. The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice.
Pawlak M; Baugé E; Bourguet W; De Bosscher K; Lalloyer F; Tailleux A; Lebherz C; Lefebvre P; Staels B
Hepatology; 2014 Nov; 60(5):1593-606. PubMed ID: 24995693
[TBL] [Abstract][Full Text] [Related]
10. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism.
Cariou B; Zaïr Y; Staels B; Bruckert E
Diabetes Care; 2011 Sep; 34(9):2008-14. PubMed ID: 21816979
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
12. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
[No Abstract] [Full Text] [Related]
13. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis.
Uno M; Kurita S; Misu H; Ando H; Ota T; Matsuzawa-Nagata N; Kita Y; Nabemoto S; Akahori H; Zen Y; Nakanuma Y; Kaneko S; Takamura T
Hepatology; 2008 Jul; 48(1):109-18. PubMed ID: 18571789
[TBL] [Abstract][Full Text] [Related]
14. RLA8-A New and Highly Effective Quadruple PPAR-
Li MH; Chen W; Wang LL; Sun JL; Zhou L; Shi YC; Wang CH; Zhong BH; Shi WG; Guo ZW
J Pharmacol Exp Ther; 2019 Apr; 369(1):67-77. PubMed ID: 30745416
[TBL] [Abstract][Full Text] [Related]
15. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Sahebkar A; Chew GT; Watts GF
Expert Opin Pharmacother; 2014 Mar; 15(4):493-503. PubMed ID: 24428677
[TBL] [Abstract][Full Text] [Related]
16. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
[TBL] [Abstract][Full Text] [Related]
17. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
18. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
19. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet.
Nagasawa T; Inada Y; Nakano S; Tamura T; Takahashi T; Maruyama K; Yamazaki Y; Kuroda J; Shibata N
Eur J Pharmacol; 2006 Apr; 536(1-2):182-91. PubMed ID: 16574099
[TBL] [Abstract][Full Text] [Related]
20. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice.
Tomita K; Oike Y; Teratani T; Taguchi T; Noguchi M; Suzuki T; Mizutani A; Yokoyama H; Irie R; Sumimoto H; Takayanagi A; Miyashita K; Akao M; Tabata M; Tamiya G; Ohkura T; Hibi T
Hepatology; 2008 Aug; 48(2):458-73. PubMed ID: 18666257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
